Abstract
The platelet-derived growth factor (PDGF-A, PDGF-B, PDGF-C, PDGF-D) family is composed of homo- and hetero-dimers that are potent mitogens for a wide variety of cell types. They exert their biological effects by binding to two receptor tyrosine kinases (α- and β-PDGFR). PDGF-AA, -AB, -BB and -CC dimers bind to the α-PDGFR with high affinity, whereas PDGF-BB and -DD dimers bind to β-PDGFR. Aberrant PDGF signaling leads to increased interstitial fluid pressure, stromal cell recruitment and neo-angiogenesis in glioblastoma multiforme (GBM) due to deregulated autocrine/paracrine signaling. Therefore, targeting the PDGFR tyrosine kinase domain with small molecule tyrosine kinase inhibitors (TKIs) alone or in combination with chemotherapy may provide therapeutic benefit in GBM. Here we review PDGFR antagonists in clinical development including novel multi-targeted TKIs.
Keywords: Platelet derived growth factor receptor, Tyrosine Kinase Inhibitors, Glioblastoma Multiforme, Clinical trials
Letters in Drug Design & Discovery
Title: The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Volume: 7 Issue: 4
Author(s): Michael A. Badruddoja, Emad Elquza, James Welsh, Laurence Cooke, Abhay Sanan, Baldassrre Stea and Daruka Mahadavan
Affiliation:
Keywords: Platelet derived growth factor receptor, Tyrosine Kinase Inhibitors, Glioblastoma Multiforme, Clinical trials
Abstract: The platelet-derived growth factor (PDGF-A, PDGF-B, PDGF-C, PDGF-D) family is composed of homo- and hetero-dimers that are potent mitogens for a wide variety of cell types. They exert their biological effects by binding to two receptor tyrosine kinases (α- and β-PDGFR). PDGF-AA, -AB, -BB and -CC dimers bind to the α-PDGFR with high affinity, whereas PDGF-BB and -DD dimers bind to β-PDGFR. Aberrant PDGF signaling leads to increased interstitial fluid pressure, stromal cell recruitment and neo-angiogenesis in glioblastoma multiforme (GBM) due to deregulated autocrine/paracrine signaling. Therefore, targeting the PDGFR tyrosine kinase domain with small molecule tyrosine kinase inhibitors (TKIs) alone or in combination with chemotherapy may provide therapeutic benefit in GBM. Here we review PDGFR antagonists in clinical development including novel multi-targeted TKIs.
Export Options
About this article
Cite this article as:
Badruddoja A. Michael, Elquza Emad, Welsh James, Cooke Laurence, Sanan Abhay, Stea Baldassrre and Mahadavan Daruka, The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review, Letters in Drug Design & Discovery 2010; 7 (4) . https://dx.doi.org/10.2174/157018010790945887
DOI https://dx.doi.org/10.2174/157018010790945887 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanoplatforms for Delivery of siRNA to the Eye
Current Pharmaceutical Design Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine An Overview of High-grade Glioma: Current and Emerging Treatment Approaches
Current Cancer Therapy Reviews Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice
Current Molecular Medicine Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications
Current Neuropharmacology Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Natural Products and Cancer Stem Cells
Current Pharmaceutical Design P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry Genomic Signatures for Individualized Treatment of Malignant Tumors
Current Drug Discovery Technologies The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
Current Medicinal Chemistry Application of the Shortest Path Algorithm for the Discovery of Breast Cancer-Related Genes
Current Bioinformatics IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Synthesis of Silica Based Nanoparticles Against the Proliferation of Human Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets